miR-155 augments CD8 <sup>+</sup> T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic γ <sub>c</sub> cytokines

Yun Ji, Claudia Wrzesinski, Zhiya Yu, Jinhui Hu, Sanjivan Gautam, Nga Voong Hawk, William G. Telford, Douglas C. Palmer, Zulmarie Franco, Madhusudhanan Sukumar,

Proceedings of the National Academy of Sciences · 2014 · 118 citations · 33 references

DOIFull text

Open access

Concepts

Abstract

Lymphodepleting regimens are used before adoptive immunotherapy to augment the antitumor efficacy of transferred T cells by removing endogenous homeostatic "cytokine sinks." These conditioning modalities, however, are often associated with severe toxicities. We found that microRNA-155 (miR-155) enabled tumor-specific CD8(+) T cells to mediate profound antitumor responses in lymphoreplete hosts that were not potentiated by immune-ablation. miR-155 enhanced T-cell responsiveness to limited amounts of homeostatic γc cytokines, resulting in delayed cellular contraction and sustained cytokine production. miR-155 restrained the expression of the inositol 5-phosphatase Ship1, an inhibitor of the serine-threonine protein kinase Akt, and multiple negative regulators of signal transducer and activator of transcription 5 (Stat5), including suppressor of cytokine signaling 1 (Socs1) and the protein tyrosine phosphatase Ptpn2. Expression of constitutively active Stat5a recapitulated the survival advantages conferred by miR-155, whereas constitutive Akt activation promoted sustained effector functions. Our results indicate that overexpression of miR-155 in tumor-specific T cells can be used to increase the effectiveness of adoptive immunotherapies in a cell-intrinsic manner without the need for life-threatening, lymphodepleting maneuvers.

References

33